search icon
      blog search icon

      What Led The Lantheus (LNTH) Stock To Increase In Premarket Session? - Stocks Telegraph

      By Fahim Awan

      Published on

      July 30, 2021

      10:05 AM UTC

      What Led The Lantheus (LNTH) Stock To Increase In Premarket Session? - Stocks Telegraph

      The shares of Lantheus Holdings Inc. (LNTH) are trading up 3.88% in pre-market trading at the time of this writing. Thursday’s session ended with LNTH stock up 0.15% at $27.05. Volume for Lantheus stock was 0.36 million shares, a decrease from the 0.74 million shares averaged daily within the last 50 days. During the last 12 months, LNTH stock has increased by 72.18%, and it has gained 5.58% in the past week.

      The LNTH stock has gained 15.01% over the past three months, and the stock has gained 68.64% over the past six months. LNTH is currently valued at $1.82 billion, and its outstanding shares were 67.09 million. Lantheus stock is rising since the company announced the only FDA-approved AI-enabled PSMA application.

      What was the purpose of the LNTH app?

      As a parent company, Lantheus Holdings owns Lantheus Medical Imaging, Progenics Pharmaceuticals, Inc. and Exini Diagnostics AB. A fully integrated provider of imaging diagnostics, therapy, and artificial intelligence solutions for finding, fighting, and following serious medical conditions, LNTH is an established leader in the field. With its DEFINITY Vial agent and products like PYLARIFY, TechneLite, AZEDRA, and RELISTOR, LNTH Stock offers a broad range of products. LNTH has offices in New York, New Jersey, Canada and Sweden. Its headquarters is in North Billerica, Massachusetts.

      LNTH stock announced the approval of 510(k) by the US Food and Drug Administration (FDA) of its subsidiary; EXINI Diagnostics AB. LNTH-subsidiary received approval for its aPROMISE (automated PROstate Cancer Molecular Imaging Standardized Evaluation) digital application. Clinical participants will be able to use PYLARIFY (piflufolastat F 18) with aPROMISE to improve their PSMA PET/CT assessment’s efficiency and reproducibility.

      The FDA recently approved PyLARIFY, the first and only commercially available PET imaging agent targeting PSMA. AI-based PSMA PET/CT imaging evaluation software, aPROMISE, employs deep learning to allow healthcare professionals to perform quantitative analysis of PSMA PET images in prostate cancer. Deep learning training and validation of the software was performed across more than 3,000 PSMA images up until now.

      Leading prostate cancer experts developed PROMISE criteria to standardize quantitative evaluation of prostate cancer lesions using prostate-specific membrane antigen (PSMA) PET/CT. By using a comprehensive and automated approach to patient evaluation, aPROMISE allows clinicians to make routine use of a comprehensive, automated assessment of prostate cancer lesions.

      It is a solution for automating body segmentation and marking, quantifying and reporting suspicious lesions in their anatomical context. As a result of aPROMISE, clinicians’ PSMA PET/CT image assessments have been more efficient and reproducible and have demonstrated an improved consistency in the analysis and reporting of these images.

      LNTH Stock perspective:

      The FDA has cleared Lantheus (LNTH)’s AI-enabled digital application aPROMISE, which expands its PSMA platform. As a leading provider of PSMA quantification and reporting, LNTH will be able to allow clinicians to make better, more informed treatment decisions for their prostate cancer patients.

      More From Stocks telegraph